Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Davar D, et al. Among authors: kirkwood jm. Cancer Cell. 2024 Nov 11;42(11):1898-1918.e12. doi: 10.1016/j.ccell.2024.10.007. Epub 2024 Oct 31. Cancer Cell. 2024. PMID: 39486411 Free article. Clinical Trial.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Schadendorf D, et al. Among authors: kirkwood jm. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. J Immunother Cancer. 2024. PMID: 38485189 Free PMC article. Clinical Trial.
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas.
Karapetyan L, Li A, Vargas De Stefano D, Abushukair HM, Al-Bzour AN, Knight A, Layding C, Wang H, Xu J, Yao J, Song X, Joy M, Nguyen J, Moran-Segura C, Bruno S, Sander C, Messina J, Mule JJ, Storkus WJ, Kirkwood JM. Karapetyan L, et al. Among authors: kirkwood jm. J Immunother Cancer. 2024 Nov 12;12(11):e009231. doi: 10.1136/jitc-2024-009231. J Immunother Cancer. 2024. PMID: 39537211 Free PMC article.
Genomic Classification of Cutaneous Melanoma.
Cancer Genome Atlas Network. Cancer Genome Atlas Network. Cell. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044. Cell. 2015. PMID: 26091043 Free PMC article.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.
Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea AM, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P; Melanoma World Society Study Group. Hauschild A, et al. Among authors: kirkwood jm. Lancet Oncol. 2025 Jan;26(1):12-14. doi: 10.1016/S1470-2045(24)00627-2. Lancet Oncol. 2025. PMID: 39756440 No abstract available.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Gershenwald JE, et al. Among authors: kirkwood jm. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. CA Cancer J Clin. 2017. PMID: 29028110 Free PMC article.
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, Merelli B, Sileni VC, Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnaik SB, Burgess P, Jandoo T, Dummer R. Long GV, et al. Among authors: kirkwood jm. N Engl J Med. 2024 Nov 7;391(18):1709-1720. doi: 10.1056/NEJMoa2404139. Epub 2024 Jun 19. N Engl J Med. 2024. PMID: 38899716 Clinical Trial.
589 results